scorecardresearch
Tuesday, November 5, 2024
Support Our Journalism
HomeHealthFewer than 50% healthcare workers get the Covaxin shot at 6 central...

Fewer than 50% healthcare workers get the Covaxin shot at 6 central hospitals in Delhi

Out of a target of 1,250, a total of 551 health workers administered Covaxin on 16 and 18 January, shows data. While 314 got the shot Saturday, the number fell to 237 Monday.

Follow Us :
Text Size:

New Delhi: Fewer than 50 per cent healthcare workers received Bharat Biotech’s Covaxin at the six Central government hospitals in the national capital on the first two days of Covid-19 vaccination, showed data obtained from the hospitals and respective district officials.

Out of a target of 1,250, a total of 551 (44.08 per cent) health workers were administered the vaccine on 16 and 18 January, data showed. While 314 beneficiaries received the jab on the first day of the drive Saturday, the number fell to 237 Monday.

According to the Union Ministry of Health and Family Welfare’s directions, each vaccination centre is expected to meet a target of 100 shots in a day — bringing the two-day figure for the six centres to 1,200. However, one of the Centre-run hospitals, the Ram Manohar Lohia (RML) Hospital, confirmed to ThePrint that it was asked to vaccinate 150 people on the second day.

Of the 81 hospitals in the national capital, 75 are run by the Delhi government and private players. These have been allotted the Oxford-AstraZeneca candidate Covishield, manufactured in the country by the Serum Institute of India (SII).

The six central government hospitals — All India Institute of Medical Sciences (AIIMS), Safdarjung, RML, Kalawati Saran Children’s Hospital, ESI Hospital Basaidarapur, and ESI Hospital Rohini — only received Bharat Biotech’s Covaxin last week.


Also read: Covaxin, Covishield not for everyone — manufacturers list who should avoid the Covid vaccines


Status at Central govt-run hospitals

Among the six hospitals, AIIMS showed the most variation between Day One and Day Two. As opposed to 95 people who were vaccinated Saturday, only eight health workers took the vaccine Monday, showed the data.

Graphic: Ramandeep Kaur/ThePrint
Graphic: Ramandeep Kaur/ThePrint

On the first day, an adverse event was reported at AIIMS when a security guard “showed some symptoms and developed an allergy” following the vaccination. He was then hospitalised, and discharged after two days under observation, but the incident led to panic among other healthcare workers.

A member of the AIIMS Resident Doctors’ Association (RDA), who didn’t wish to be named, said, “I have been sceptical about this vaccine (Covaxin) throughout but after learning about what the security guard went through, it is but natural to be hesitant.”

The AIIMS RDA as well as RML Hospital even took this up with their respective medical superintendents Saturday through a common representation they filed in view of the adverse event. ThePrint has seen the representation.

It expressed that “doctors might not turn up in huge numbers since they are not keen to get Covaxin due to concerns about efficacy”. It also requested that Covishield be made available at AIIMS.

At Safdarjung, only 20 persons were vaccinated on the second day as opposed to 72 earlier, confirmed the hospital spokesperson. ESI Hospital Basaidarapu saw only 27 healthcare workers being administered Covaxin Monday as compared to 32. At its other branch in Rohini, only 37 healthcare workers got Covaxin Monday.

However, at Kalawati Saran Children’s Hospital and RML, there was an improvement in numbers on the second day.

At Kalawati, which is situated on the Lady Hardinge Medical College (LHMC) campus, 76 people were administered Covaxin Monday in comparison to 26 on the first day. Asked what helped in a higher turnout on the second day despite hesitancy among people about Covaxin, LHMC medical director Dr N.N. Mathur said, “I took the jab myself on Saturday and shared visuals of the same on social media. Perhaps these things help reassure our staff that it is safe to do so.”

At RML Hospital, 69 workers were vaccinated on Day Two out of the targeted 150, medical superintendent Dr A.K. Rana confirmed.

Lower turnout across Delhi on Day 2

Meanwhile, as many as 3,598 of the targeted 8,136 healthcare workers were vaccinated across 81 centres in the national capital Monday as opposed to 4,319 on the first day of the vaccination drive.

According to the Delhi government’s record, 26 adverse events were reported Monday, of which two were severe cases including one hospitalisation. ThePrint couldn’t independently verify more details about the particular case.

In Delhi’s South district, only 316 of a target of 900 healthcare workers were vaccinated across nine hospitals. In West, 457 of 1,100 beneficiaries were vaccinated Saturday at 11 centres. In North West district, the turnout was more than 50 per cent — 575 workers against a target of 1,100 at 11 centres.


Also read: Bharat Biotech secures Letter of Comfort from govt for additional 45 lakh vaccine doses


 

Subscribe to our channels on YouTube, Telegram & WhatsApp

Support Our Journalism

India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that.

Sustaining this needs support from wonderful readers like you.

Whether you live in India or overseas, you can take a paid subscription by clicking here.

Support Our Journalism

2 COMMENTS

  1. The report says out of 1250, 551 doctors took it which is 44.08% which is very good percentage.

    Also, Pfizer, Sinopharma and other drugs also having side effects and does not give 100% guarantee.

    The author wants to show Covaxin in negative way. I dont understand his intention.

  2. If doctors themselves are not taking Covaxin, then it sends a loud and clear message that they don’t trust the country’s regulatory authorities.

    How will public then trust the government regarding these emergency approved vaccines?

    We all want an indigenous vaccine to be successful, but there should be enough transparency regarding it’s data and trials. Those who are willing to take the risk can do so but it is clear they will be basically participating in a clinical trial mode.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular